Literature DB >> 21359971

Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.

Thomas Müller1, Constanze Jugel, Reinhard Ehret, Georg Ebersbach, Gunar Bengel, Siegfried Muhlack, Fabian Klostermann.   

Abstract

Levodopa/carbidopa (LD/CD) application elevates total plasma homocysteine (thcys). We determined thcys-, LD- and 3-O-methyldopa (3-OMD) concentrations in 28 patients with Parkinson's disease (PD) on a LD/CD duodenal gel treatment. We found a distinct thcys increase (29.52 ± 28.98 μmol/l [median ± SD]) above the 15 μmol/l threshold and a significant (R = 0.7) correlation between LD and 3-OMD. thcys ascent was observed in relation with the onset of atherosclerosis, non-motor symptoms and polyneuropathy in PD patients in the long term.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21359971     DOI： 10.1007/s00702-011-0614-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  25 in total

1.  Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

2.  Effects of homocysteine on the dopaminergic system and behavior in rodents.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Karam F A Soliman; Clivel G Charlton
Journal:  Neurotoxicology       Date:  2005-06       Impact factor: 4.294

Review 3.  Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.

Authors:  Thomas Müller
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

4.  Bound homocysteine, cysteine, and cysteinylglycine distribution between albumin and globulins.

Authors:  Glen L Hortin; Nitin Seam; Gerard T Hoehn
Journal:  Clin Chem       Date:  2006-10-26       Impact factor: 8.327

5.  Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells.

Authors:  Y Furukawa; N Tomioka; W Sato; E Satoyoshi; K Hayashi; S Furukawa
Journal:  FEBS Lett       Date:  1989-04-24       Impact factor: 4.124

6.  Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.

Authors:  P Benetello; M Furlanut; M Fortunato; F Pea; M Baraldo
Journal:  Pharmacol Res       Date:  1997-04       Impact factor: 7.658

7.  Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.

Authors:  Thomas Müller; Undine E Lang; Siegfried Muhlack; Jacub Welnic; Rainer Hellweg
Journal:  Clin Neuropharmacol       Date:  2005 Sep-Oct       Impact factor: 1.592

8.  Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture.

Authors:  Keiko Imamura; Takao Takeshima; Kazuhiro Nakaso; Kenji Nakashima
Journal:  Neuroreport       Date:  2007-08-27       Impact factor: 1.837

9.  Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration.

Authors:  Thomas Müller; Kathrin Renger; Wilfried Kuhn
Journal:  Arch Neurol       Date:  2004-05

10.  Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats.

Authors:  Goutam Chandra; Prasanta K Gangopadhyay; Karuppagounder S Senthil Kumar; Kochupurackal P Mohanakumar
Journal:  Brain Res       Date:  2006-02-17       Impact factor: 3.252
View more
  17 in total

1.  Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.

Authors:  Masoud Alirezaei; Zeynab Khoshdel; Omid Dezfoulian; Marzyeh Rashidipour; Vahideh Taghadosi
Journal:  J Physiol Sci       Date:  2015-02-11       Impact factor: 2.781

Review 2.  Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.

Authors:  Johan Virhammar; Dag Nyholm
Journal:  Ther Adv Neurol Disord       Date:  2016-12-01       Impact factor: 6.570

3.  Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation.

Authors:  Sophie M Lehnerer; Urban M Fietzek; Michael Messner; Andres O Ceballos-Baumann
Journal:  J Neural Transm (Vienna)       Date:  2014-04-08       Impact factor: 3.575

Review 4.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

5.  Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Authors:  Thomas Müller; Dirk Woitalla; Siegfried Muhlack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

6.  Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.

Authors:  Carsten Buhmann; R Hilker; P Lingor; C Schrader; J Schwarz; M Wolz; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-22       Impact factor: 3.575

7.  Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence.

Authors:  Maryam Rezaei; Masoud Alirezaei
Journal:  J Physiol Sci       Date:  2014-01-25       Impact factor: 2.781

Review 8.  Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.

Authors:  Thomas Müller; Horst Baas; Jan Kassubek; Peter Riederer; Peter Paul Urban; Christoph Schrader; Heinz Reichmann; Dirk Woitalla; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2015-11-14       Impact factor: 3.575

Review 9.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep

10.  Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.

Authors:  Thomas Müller; Isabel Trommer; Siegfried Muhlack; Bernhard K Mueller
Journal:  J Neural Transm (Vienna)       Date:  2016-02-15       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.